WEBINAR RECORDED ON SEPTEMBER 26, 2019
Part I: Using TPMT and NUDT15 Pharmacogenetics to Reduce Thiopurines-related ADRs.
Part II: Pharmacogenetics experience at Boston Children’s Hospital
Gunter Scharer, MD, PhD
Dr. Scharer is a board-certified medical geneticist with 15+ years of clinical and laboratory experience. He is a renowned geneticist with deep experience in rare disorders and mitochondrial disease. Dr. Scharer is a member of the CPIC and Pharmacogenomics Research Network (PGRN).
Shannon Manzi, PharmD
Dr. Manzi is a clinical pharmacist and has practiced pediatric pharmacy for more than 20 years. She serves as the Director of the Clinical pharmacogenomics Service at Boston Children’s Hospital and is an Assistant Professor of Pediatrics at Harvard Medical School. Dr. Manzi is the member of the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Insights into TPMT and NUDT15
Learn more about TPMT and NUDT15: two critical PGx genes to guide thiopurines dosing and reduce ADRs.
Order the test
Learn more about RPRD’s NT (NUDT15 and TPMT) panel.